Clinical Trials for Ovarian Cancer

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable solid tumors (excluding NSCLC) harboring activating HER2 mutations, who have progressed on standard therapy or have no satisfactory alternatives. Patients receive BAY2927088, an oral reversible tyrosine kinase inhibitor targeting mutant HER2 and EGFR.

ClinicalTrials.gov ID: NCT06760819

Phase II Open-Label Multi-Cohort Study Evaluating CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Patients With Advanced Chemorefractory Colorectal, Pancreatic, or Other Solid Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adults with advanced or metastatic colorectal, pancreatic, biliary, gastroesophageal, urothelial, ovarian, or non-small cell lung adenocarcinomas refractory to standard chemotherapy, this study combines the mitochondrial metabolism inhibitor devimistat (CPI-613) with hydroxychloroquine and either 5-FU or gemcitabine depending on tumor type. Eligible patients must have measurable disease and good performance status (ECOG 0-1, some 2 with approval).

ClinicalTrials.gov ID: NCT05733000

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adults with platinum‑resistant high‑grade serous ovarian/primary peritoneal/fallopian tube cancer or clear cell gynecologic cancers (ovarian, endometrial, vaginal, vulvar, cervical) with measurable disease after prior lines of therapy; excludes prior PD‑1/PD‑L1/PD‑L2 or CTLA‑4 exposure and platinum‑refractory disease. Patients receive lorigerlimab (MGD019), an investigational bispecific checkpoint inhibitor targeting PD‑1 and CTLA‑4, given IV every 21 days until progression or intolerance.

ClinicalTrials.gov ID: NCT06730347

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma harboring a PI3K/AKT/mTOR pathway alteration, post 1–4 prior regimens including platinum and typically a checkpoint inhibitor, receive sapanisertib (mTORC1/2 inhibitor) plus serabelisib (PI3Kα inhibitor) combined with paclitaxel; a substudy adds an insulin‑suppressing diet. Key exclusions include uncontrolled CNS disease, significant cardiac issues, CYP3A modulator use, gastric pH–raising meds, QTc >480 ms, and poorly controlled diabetes or insulin use.

ClinicalTrials.gov ID: NCT06463028

A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Plus Defactinib (FAK Inhibitor) in Recurrent Gynecological Cancers (DURAFAK)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Enrolling adult women with recurrent/progressive gynecologic cancers (e.g., endometrioid, mucinous ovarian, high-grade serous ovarian, others) harboring MAPK-pathway alterations (RAS activation/mutation, BRAF class I–III mutation, and/or NF1 loss), ECOG 0–1, and prior systemic therapy; excludes prior RAF/MEK inhibitor exposure and LGSOC. Treatment is oral avutometinib (dual RAF/MEK “clamp”) plus defactinib (FAK inhibitor).

ClinicalTrials.gov ID: NCT05512208

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Newly diagnosed, high-grade non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO IIIB/C–IV) eligible for neoadjuvant chemo and interval debulking; excludes low-grade, clear cell, mucinous, prior therapy, and planned bevacizumab. Compares standard neoadjuvant/adjuvant carboplatin-paclitaxel (with SOC maintenance allowed) versus the same plus intraperitoneal IMNN-001, a DNA-mediated IL-12 immunotherapy designed for local IL-12 expression to enhance IFN-γ/NK/CD8+ activity and reduce peritoneal immunosuppression.

ClinicalTrials.gov ID: NCT06915025

A Phase 2 Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study for adult women with recurrent/persistent ARID1A-mutated clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal carcinoma (≥50% histology; measurable disease; ≥2 prior cytotoxic regimens or platinum-resistant/refractory; no prior PARP inhibitor or temozolomide). Patients receive senaparib (oral PARP1/2 inhibitor) daily plus low-dose temozolomide on a 28-day cycle to assess objective response and safety.

ClinicalTrials.gov ID: NCT06617923

Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Women ≥18 with CLDN6-positive, advanced platinum‑resistant high‑grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer (1–3 prior lines; ECOG 0–1) receive TORL‑1‑23, a CLDN6-targeted antibody–drug conjugate delivering MMAE to disrupt microtubules, given IV q3wk with prophylactic pegfilgrastim. Excludes non–high-grade epithelial histologies, primary platinum-refractory disease, prior CLDN6/MMAE-ADC exposure, active CNS disease, and grade ≥2 neuropathy.

ClinicalTrials.gov ID: NCT06690775

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer after ≥4 cycles first-line platinum and 6 cycles second-line carboplatin doublet (ECOG 0–1) randomized to maintenance sacituzumab tirumotecan (TROP2-directed antibody–drug conjugate delivering a belotecan-derived topoisomerase I inhibitor) with optional bevacizumab versus standard-of-care maintenance with optional bevacizumab. Excludes platinum-resistant/refractory and non-epithelial/borderline histologies and patients with significant ocular disease, active IBD, uncontrolled CV/cerebrovascular disease, prior severe ILD/pneumonitis, or active CNS metastases.

ClinicalTrials.gov ID: NCT06824467

A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Single-arm study of INCB123667, an oral selective CDK2 inhibitor targeting Cyclin E–driven cell-cycle progression, in adults with high-grade serous ovarian/fallopian tube/primary peritoneal cancer that is platinum-resistant and CCNE1/Cyclin E1–overexpressing. Eligible patients have had 1–4 prior regimens with prior bevacizumab (and mirvetuximab if FRα-positive) unless contraindicated; exclusions include non–HGS histology, primary platinum-refractory disease, and active CNS metastases.

ClinicalTrials.gov ID: NCT07023627